This mechanism helps reduce Aβ production in the hippocampus of AD model mice, decrease senile plaque formation, and improve cognitive function and pathological changes (Figure 6) These findings reveal a new role for KIF9 in AD and provide a scientific basis for developing KIF9‐based therapies to address learning and memory deficits in AD patients. Here, KIF9 is linked to Alzheimer disease.